Assessment of Stage Two Hypertension Treatment Plans Written by Generative AI
Document Type
Article
Publication Date
4-18-2026
Publication Title
J Clin Med
Abstract
Background/Objectives: As use of large language models (LLMs) in clinical practice, in medical education, and by patients increases, it is essential to ensure that information provided is accurate and safe. Our objective was to compare stage two hypertension treatment plans generated by popular LLMs. Methods: ChatGPT (GPT-4o), Claude (Claude 4 Sonnet), ClinicalKey AI, Microsoft Copilot (Wave 2), DeepSeek-V3-0324, Dyna AI, Google Gemini (2.5 Flash), Grok (version 3), Meta AI assistant (Llama 4 Maverick), OpenEvidence (version 2.0), Perplexity (Sonar backend model), and Pi (Inflection-2.5) were prompted to generate a treatment plan for stage two hypertension. Six blinded reviewers scored each response in three domains: adherence to clinical guidelines, detail/clarity, and reliability/safety. Results: Perplexity received the highest composite score (8.17 out of 9), followed by OpenEvidence (7.92 out of 9). Dyna AI had the lowest overall score (3.75 out of 9). Perplexity (3.00 out of 3), Grok (2.83 out of 3), and OpenEvidence (2.75 out of 3) had the highest scores for detail/clarity, while Dyna AI had the lowest for both detail/clarity (1.00 out of 3) and reliability/safety (1.00 out of 3). ChatGPT had the highest score for adherence to guidelines (2.75 out of 3) while Pi had the lowest (1.58 out of 3). Kruskal-Wallis test showed p < 0.05 across sub-score domains and composite scores. Conclusions: LLMs tended to adhere to clinical guidelines and provide detailed responses but often did not provide sources or instruct users to see a healthcare professional. There was notable variability in quality, and medicine-specific LLMs were not superior to popular LLMs.
Volume
15
Issue
8
Recommended Citation
Metzger T, Hossain Z, Park K, Vu S, Dixon S, Taylor TAH. Assessment of Stage Two Hypertension Treatment Plans Written by Generative AI. J Clin Med. 2026;15(8):3103. Published 2026 Apr 18. doi:10.3390/jcm15083103
DOI
10.3390/jcm15083103
ISSN
2077-0383
PubMed ID
42074904